Bolt Biotherapeutics
BOLT
32 hedge funds and large institutions have $12.2M invested in Bolt Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 5 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.51% less ownership
Funds ownership: 2.97% → 2.45% (-0.51%)
11% less funds holding
Funds holding: 36 → 32 (-4)
28% less capital invested
Capital invested by funds: $17M → $12.2M (-$4.8M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.5K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$40.6K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$27.9K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.8K |
| 5 |
Renaissance Technologies
New York
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.78M |
| 2 |
NM
Newtyn Management
New York
|
-$616K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$473K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$85.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$19.6K |
BOLT Hedge Fund Activity: Q3 2024 in Review
32 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2024, worth a combined $12.2M — down 28% from $17M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BOLT and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $86.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.78M sold.
- 32 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2024, down from 36 in Q2 2024.
- Funds reported $12.2M of Bolt Biotherapeutics stock for Q3 2024, down 28% quarter-over-quarter.
- 1 fund opened new Bolt Biotherapeutics positions in Q3 2024 and 5 closed out, a net change of -4 holders.
- The largest Bolt Biotherapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $86.5K added.
- The largest Bolt Biotherapeutics seller in Q3 2024 was Citadel Advisors, an estimated $1.78M sold.
Based on aggregated 13F filings for Q3 2024.